Abstract 13485: Prevalence and Treatment of “Balloon Uncrossable” Coronary Chronic Total Occlusions
Background: In percutaneous coronary intervention (PCI) of coronary chronic total occlusions (CTOs), inability to cross the lesion with a balloon is the second most common cause of technical failure following inability to cross the lesion with a guidewire. While various techniques have been reported for such "balloon uncrossable" CTOs, the frequency and outcomes of these techniques have received limited study.
Methods: We retrospectively examined 373 consecutive CTO PCIs performed at our institution between 2005 and 2013 to determine the frequency and outcomes of “balloon uncrossable” CTOs.
Results: Mean age was 63.7 ± 8.3 years and 98.9% of the patients were men. Twenty four patients (6.4%) were found to have a "balloon uncrossable" CTO. These patients had similar clinical and angiographic characteristics compared to the other CTO PCI patients (Table). Successful crossing of the lesion was achieved in 22 of 24 patients (91.7%) using a variety of techniques, such as successive balloon inflations (43.5%), microcatheter advancement (21.7%), laser (8.7%), increased guide catheter support (13.0%), and subintimal lesion crossing (13.0%) (Figure). Patients with “balloon uncrossable” CTOs had longer procedure time (184.5 ± 77.9 vs. 134.0 ± 69.0 min, p<0.01), fluoroscopy time (55.2 ± 24.9 vs. 37.9 ± 20.8 min, p<0.01), and received higher contrast volume (404.4 ± 137.9 vs. 351.7 ± 138.5 ml, p=0.085), but had similar incidence of major complications (8.3% vs. 3.2%, p=0.25) compared to patients without “balloon uncrossable” CTOs.
Conclusion: “Balloon uncrossable” CTOs occur in 6.4% of contemporary CTO PCIs and can be successfully treated in most patients using a variety of techniques.
- Complete total occlusion
- Percutaneous coronary intervention (PCI)
- Coronary artery disease
- Coronary vessels
Author Disclosures: S. Patel: None. N. Pokala: None. R. Menon: None. A. Kotsia: None. V. Raja: None. G. Christopoulos: None. T. Michael: None. B. Rangan: None. D. Sherbet: None. V. Patel: None. S. Abdullah: None. J. Hastings: None. J. Grodin: None. S. Banerjee: Research Grant; Significant; Gilead. Honoraria; Significant; Covidien, Medtronic. Ownership Interest; Significant; MDCARE Global, HygeiaTel. E. Brilakis: Research Grant; Significant; Guerbet. Honoraria; Significant; Sanofi, Janssen, St. Jude Medical, Terumo, Asahi, Boston Scientific. Other; Significant; Spouse is an employee of Medtronic.
- © 2014 by American Heart Association, Inc.